Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856865 · ClinicalTrials.gov registry record · Phase 1
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
A Phase 1 study of Food Allergy, sponsored by Alladapt Immunotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 15
- Study locations
NCT04856865 is a Phase 1 study of Food Allergy that has completed, run by Alladapt Immunotherapeutics. The registered enrollment target is 73 participants, below the 960-participant average among 17 other Food Allergy trials with a reported enrollment target (92% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT04856865, a Phase 1 study of Food Allergy, has completed, sponsored by Alladapt Immunotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
Conditions Studied
Interventions
- BIOLOGICAL Low dose ADP101
- BIOLOGICAL High dose ADP101
- BIOLOGICAL Pooled Placebo
Study Locations (15)
California
- Study Site - Mission Viejo
- Study Site - Rolling Hills Estates
- Study Site - San Diego
Georgia
- Study Site - Atlanta
- Study Site - Marietta
Colorado
- Study Site - Denver
Florida
- Study Site - Tampa
Illinois
- Study Site - Normal
Michigan
- Study Site - Ann Arbor
North Carolina
- Study Site - Chapel Hill
Ohio
- Study Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2022-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04856865
The ClinicalTrials.gov registry entry for NCT04856865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 960-participant average among 17 other Food Allergy trials with a reported enrollment target (92% lower). The listed sponsor is Alladapt Immunotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Food Allergy appearing as the primary indexed condition, and to 3 interventions - of which Low dose ADP101 is the first listed.
NCT04856865 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT04856865 about?
NCT04856865 is a clinical study titled "ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults". The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
What is the current status of trial NCT04856865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2021-04-20. Estimated completion is 2022-12-13.
What conditions does trial NCT04856865 study?
This clinical trial studies the following conditions: Food Allergy.
What interventions are being tested in trial NCT04856865?
The interventions under investigation include: Low dose ADP101 (BIOLOGICAL), High dose ADP101 (BIOLOGICAL), Pooled Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT04856865?
This trial is sponsored by Alladapt Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04856865 being conducted?
This trial has 15 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
RECRUITING · Phase 1
-
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
RECRUITING · Phase 1
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
COMPLETED · Phase 1
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
RECRUITING
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.